Mechanisms underlying improvements in ejection fraction with carvedilol in heart failure

Mathew S Maurer1, Jonathan D Sackner-Bernstein, Lyna El-Khoury Rumbarger

  • 1Division of Cardiology, Columbia Presbyterian Medical Center, New York, NY, USA.

Insights

Beta-blocker therapy with carvedilol improved ejection fraction (EF) in heart failure patients. Heart rate reduction significantly contributed to these EF improvements, alongside increased contractility and reduced afterload.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Beta-blocker therapy is linked to improved ejection fraction (EF) in heart failure.
  • The specific mechanisms driving EF improvement (heart rate reduction, inotropism, afterload reduction, reverse remodeling) remain unclear.

Purpose of the Study:

  • To quantify the contributions of heart rate (HR) reduction, contractility, and afterload reduction to EF improvements with carvedilol therapy.

Main Methods:

  • Serial 3D echocardiography and blood pressure measurements were taken in 29 heart failure patients over 12 months.
  • Left ventricular contractility, total peripheral resistance, and arterial elastance were derived from these measurements.
  • Changes in EF were correlated with changes in HR, contractility, and peripheral resistance.

Main Results:

  • Carvedilol therapy increased EF by 7 percentage points after 6 months (from 25% to 32%).
  • This increase was primarily driven by stroke volume, with no significant change in end-diastolic volume.
  • EF improvement correlated with decreased HR, increased contractility, and decreased total peripheral resistance.

Conclusions:

  • Decreased heart rate accounted for approximately 60% of the EF increase.
  • Improved chamber contractility contributed about 30%, and afterload reduction contributed less than 20%.
Abstract

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...